Agenus energizes IO development after engagement at ASCO2026 in Chicago

Agenus energizes IO development after engagement at ASCO2026 in Chicago
Agenus energized by ASCO2026

Agenus returned from several days in Chicago at ASCO2026 invigorated to advance immuno-oncology research for patients.

The company used the conference to network with IO experts, participate in scientific sessions, and renew ties within the oncology field. The event is considered a pivotal gathering for scientific exchange and collaboration among oncology professionals. Agenus stated it is now focused on translating insights from the conference into further developments for patient care.

Earlier this year, Agenus reported a median overall survival of 16.6 months from its BOT plus BAL regimen in checkpoint-refractory melanoma patients, according to company data. The results were observed in a heavily treated patient population. Agenus continues to update the oncology community on its clinical progress.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.